Anti-Hu CD30 FITC

Anti-Hu CD30 FITC
Regulatory status
RUO
Antigen
CD30
Clone
Ber-H8
Format
FITC
Reactivity
Human
Application
FC (QC tested)
Excitation laser
blue (488 nm)
Variant
100 tests
1F-153-T100
In stock

25 tests
1F-153-T025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock
Product details
References
Isotype
Mouse IgG1 kappa
Specificity
The mouse monoclonal antibody Ber-H8 recognizes extracellular part of CD30 (Ki-1 antigen), a 105 kDa single chain glycoprotein expressed on Hodgkin's and Reed-Sternberg cells; it is also found in Burkitt's lymphomas, virus-infected T and B lymphocytes, and on normal B and T lymphocytes after activation (T lymphocytes that produce Th2-type cytokines and on CD4+/CD8+ T lymphocytes that co-express CD45RO and the IL4 receptor).
Workshop
HLDA III: WS Code A171; HLDA IV: WS Code A105; HLDA V: WS Code A042
Application
FC (QC tested)
Application details
Flow cytometry: The reagent is designed for analysis of human blood cells using 4 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.
Reactivity
Human
Other names
Ki-1, TNFRSF8, CD30L receptor, D1S166E
Preparation
The purified antibody is conjugated with fluorescein isothiocyanate (FITC) under optimum conditions. The conjugate is purified by size-exclusion chromatography.
Formulation
Stabilizing phosphate buffered saline (PBS) solution containing 15mM sodium azide
Storage and handling
Store in the dark at 2-8°C. Do not freeze. Avoid prolonged exposure to light. Do not use after expiration date stamped on vial label.
Exbio licence note
Unless indicated otherwise, all products are For Research Use Only and not for diagnostic use. In vivo diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s. © 2019 EXBIO Praha, a.s. All rights reserved.

General references:

Wright CW, Rumble JM, Duckett CS: CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J Biol Chem. 2007 Apr;282(14):10252-62.
PubMed
Zeiser R, Nguyen VH, Hou JZ, Beilhack A, Zambricki E, Buess M, Contag CH, Negrin RS: Early CD30 signaling is critical for adoptively transferred CD4+CD25+ regulatory T cells in prevention of acute graft-versus-host disease. Blood. 2007 Mar 1;109(5):2225-33.
PubMed
Kusanovic JP, Romero R, Hassan SS, Gotsch F, Edwin S, Chaiworapongsa T, Erez O, Mittal P, Mazaki-Tovi S, Soto E, Than NG, Friel LA, Yoon BH, Espinoza J: Maternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnancies. J Matern Fetal Neonatal Med. 2007 Aug 28:1-12
PubMed
Bekiaris V, Withers D, Glanville SH, McConnell FM, Parnell SM, Kim MY, Gaspal FM, Jenkinson E, Sweet C, Anderson G, Lane PJ: Role of CD30 in B/T segregation in the spleen. J Immunol. 2007 Dec 1;179(11):7535-43.
PubMed
Polte T, Behrendt AK, Hansen G: Direct evidence for a critical role of CD30 in the development of allergic asthma. J Allergy Clin Immunol. 2006 Oct;118(4):942-8.
PubMed
Kennedy MK, Willis CR, Armitage RJ: Deciphering CD30 ligand biology and its role in humoral immunity. Immunology. 2006 Jun;118(2):143-52.
PubMed
Fischer M, Harvima IT, Carvalho RF, Möller C, Naukkarinen A, Enblad G, Nilsson G: Mast cell CD30 ligand is upregulated in cutaneous inflammation and mediates degranulation-independent chemokine secretion. J Clin Invest. 2006 Oct;116(10):2748-56.
PubMed
Blazar BR, Levy RB, Mak TW, Panoskaltsis-Mortari A, Muta H, Jones M, Roskos M, Serody JS, Yagita H, Podack ER, Taylor PA: CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J Immunol. 2004 Sep 1;173(5):2933-41.
PubMed

Product specific references:

Aalberse JA, Kapitein B, de Roock S, Klein MR, de Jager W, van der Zee R, Hoekstra MO, van Wijk F, Prakken BJ: Cord blood CD4+ T cells respond to self heat shock protein 60 (HSP60). PLoS One. 2011;6(9):e24119.
PubMed
Falini B, Pileri S, Pizzolo G, Dürkop H, Flenghi L, Stirpe F, Martelli MF, Stein H: CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood. 1995 Jan 1;85(1):1-14.
PubMed
Berro AI, Perry GA, Agrawal DK: Increased expression and activation of CD30 induce apoptosis in human blood eosinophils. J Immunol. 2004 Aug 1;173(3):2174-83.
PubMed
Franke AC, Jung D, Ellis TM: Characterization of the CD30L binding domain on the human CD30 molecule using anti-CD30 antibodies. Hybridoma. 2000 Feb;19(1):43-8.
PubMed
Matsumoto K, Terakawa M, Miura K, Fukuda S, Nakajima T, Saito H: Extremely rapid and intense induction of apoptosis in human eosinophils by anti-CD30 antibody treatment in vitro. J Immunol. 2004 Feb 15;172(4):2186-93.
PubMed
Variant
100 tests
1F-153-T100
In stock

25 tests
1F-153-T025
Out of stock
Variant
0.1 mg
11-261-C100
In stock

0.1 mg
11-261-C100
In stock